127 related articles for article (PubMed ID: 36856058)
61. Pharmacophore based virtual screening, molecular docking, molecular dynamics and MM-GBSA approach for identification of prospective SARS-CoV-2 inhibitor from natural product databases.
Kumar BK; Faheem ; Sekhar KVGC; Ojha R; Prajapati VK; Pai A; Murugesan S
J Biomol Struct Dyn; 2022 Feb; 40(3):1363-1386. PubMed ID: 32981461
[TBL] [Abstract][Full Text] [Related]
62. Discovery of small molecule inhibitors through pharmacophore modeling, molecular docking, molecular dynamics simulation and experimental validation against myeloid cell leukemia-1 (Mcl-1).
Suleiman MR; Wang H; Huang D; Wang H; Joseph J; Huang T; Zhang F; Wang J; Cheng M
J Biomol Struct Dyn; 2021 Apr; 39(7):2512-2525. PubMed ID: 32228162
[TBL] [Abstract][Full Text] [Related]
63. Identification of Potent Small-Molecule PCSK9 Inhibitors Based on Quantitative Structure-Activity Relationship, Pharmacophore Modeling, and Molecular Docking Procedure.
Mahmoudi A; Butler AE; Banach M; Jamialahmadi T; Sahebkar A
Curr Probl Cardiol; 2023 Jun; 48(6):101660. PubMed ID: 36841313
[TBL] [Abstract][Full Text] [Related]
64. Quantitative structure activity relationship and molecular simulations for the exploration of natural potent VEGFR-2 inhibitors: an
Sharma N; Sharma M; Rahman QI; Akhtar S; Muddassir M
J Biomol Struct Dyn; 2021 May; 39(8):2806-2823. PubMed ID: 32363995
[TBL] [Abstract][Full Text] [Related]
65. Screening of inhibitors as potential remedial against Ebolavirus infection: pharmacophore-based approach.
Sankar M; K L; Jeyachandran S; Pandi B
J Biomol Struct Dyn; 2021 Feb; 39(2):395-408. PubMed ID: 31928158
[TBL] [Abstract][Full Text] [Related]
66. Scaffold identification and drug repurposing for finding potential Dengue envelope inhibitors through ligand-based pharmacophore model.
Priya S; Alli VJ; Jadav SS
J Biomol Struct Dyn; 2023; 41(21):11916-11929. PubMed ID: 36709443
[TBL] [Abstract][Full Text] [Related]
67. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
68. AMPA GluA2 subunit competitive inhibitors for PICK1 PDZ domain: Pharmacophore-based virtual screening, molecular docking, molecular dynamics simulation, and ADME studies.
Rathod SB; Prajapati PB; Pal R; Mansuri MF
J Biomol Struct Dyn; 2023 Jan; 41(1):336-351. PubMed ID: 34809533
[TBL] [Abstract][Full Text] [Related]
69. Proposing novel TNFα direct inhibitor Scaffolds using fragment-docking based e-pharmacophore modeling and binary QSAR-based virtual screening protocols pipeline.
Zaka M; Abbasi BH; Durdagi S
J Mol Graph Model; 2018 Oct; 85():111-121. PubMed ID: 30149308
[TBL] [Abstract][Full Text] [Related]
70. Discovery of novel and highly potential inhibitors of glycogen synthase kinase 3-beta (GSK-3β) through structure-based pharmacophore modeling, virtual computational screening, docking and in silico ADMET analysis.
Benghanem S; Mesli F; Fatima Zohra HA; Nacereddine C; Hadjer C; Abdellatif M
J Biomol Struct Dyn; 2023 Jul; ():1-16. PubMed ID: 37498130
[TBL] [Abstract][Full Text] [Related]
71. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach.
Shanmugam V; Muthukrishnan S
J Biomol Struct Dyn; 2023; 41(23):14524-14539. PubMed ID: 36841551
[TBL] [Abstract][Full Text] [Related]
72. Insights of structure-based pharmacophore studies and inhibitor design against Gal3 receptor through molecular dynamics simulations.
Seshan G; Kanagasabai S; Ananthasri S; Kannappan B; Suvitha A; Jaimohan SM; Kanagaraj S; Kothandan G
J Biomol Struct Dyn; 2021 Nov; 39(18):6987-6999. PubMed ID: 32772816
[TBL] [Abstract][Full Text] [Related]
73. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations.
Saxena S; Abdullah M; Sriram D; Guruprasad L
J Biomol Struct Dyn; 2018 Sep; 36(12):3184-3198. PubMed ID: 28948866
[TBL] [Abstract][Full Text] [Related]
74. Identification of novel STAT3 inhibitors for liver fibrosis, using pharmacophore-based virtual screening, molecular docking, and biomolecular dynamics simulations.
Rafiq H; Hu J; Hakami MA; Hazazi A; Alamri MA; Alkhatabi HA; Mahmood A; Alotaibi BS; Wadood A; Huang X
Sci Rep; 2023 Nov; 13(1):20147. PubMed ID: 37978263
[TBL] [Abstract][Full Text] [Related]
75. Identification of novel leads as potent inhibitors of HDAC3 using ligand-based pharmacophore modeling and MD simulation.
Kumbhar N; Nimal S; Barale S; Kamble S; Bavi R; Sonawane K; Gacche R
Sci Rep; 2022 Feb; 12(1):1712. PubMed ID: 35110603
[TBL] [Abstract][Full Text] [Related]
76. Homology modeling, docking and structure-based virtual screening for new inhibitor identification of
Panda SK; Saxena S; Guruprasad L
J Biomol Struct Dyn; 2020 Apr; 38(7):1887-1902. PubMed ID: 31179839
[No Abstract] [Full Text] [Related]
77. Discovery of novel hit compounds as potential HDAC1 inhibitors: The case of ligand- and structure-based virtual screening.
Sirous H; Campiani G; Calderone V; Brogi S
Comput Biol Med; 2021 Oct; 137():104808. PubMed ID: 34478925
[TBL] [Abstract][Full Text] [Related]
78. Identifying non-nucleoside inhibitors of RNA-dependent RNA-polymerase of SARS-CoV-2 through per-residue energy decomposition-based pharmacophore modeling, molecular docking, and molecular dynamics simulation.
Aziz S; Waqas M; Mohanta TK; Halim SA; Iqbal A; Ali A; Khalid A; Abdalla AN; Khan A; Al-Harrasi A
J Infect Public Health; 2023 Apr; 16(4):501-519. PubMed ID: 36801630
[TBL] [Abstract][Full Text] [Related]
79. Identification of potential histone deacetylase1 (HDAC1) inhibitors using multistep virtual screening approach including SVM model, pharmacophore modeling, molecular docking and biological evaluation.
Krishna S; Lakra AD; Shukla N; Khan S; Mishra DP; Ahmed S; Siddiqi MI
J Biomol Struct Dyn; 2020 Jul; 38(11):3280-3295. PubMed ID: 31411124
[TBL] [Abstract][Full Text] [Related]
80. Identification of potent human carbonic anhydrase IX inhibitors: a combination of pharmacophore modeling, 3D-QSAR, virtual screening and molecular dynamics simulations.
Chahal V; Nirwan S; Pathak M; Kakkar R
J Biomol Struct Dyn; 2022 Jul; 40(10):4516-4531. PubMed ID: 33317405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
